Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

$ 4.40 +0.22 (5.26%)
Day High: 4.45
Day Low:  4.14
Volume:    310,542
4:00 PM ET
Dec 2, 2016

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations

Nov 15, 2016 / 3:00 PM ET
Aug 24, 2016 / 3:30 PM CT